Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients

J Gastroenterol. 2020 Feb;55(2):227-243. doi: 10.1007/s00535-019-01633-2. Epub 2019 Oct 10.

Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are characterized by the accumulation of excess hepatic fat. However, in the progression from NASH to cirrhosis, hepatic fat is often lost. Our aim was to elucidate the mechanism underlying hepatic fat loss during NASH progression.

Methods: Liver biopsies were performed at The University of Tokyo Hospital between November 2011 and March 2016 on 146 patients with NAFLD and 14 patients with cryptogenic cirrhosis who were not being treated with any diabetes or dyslipidemia drugs. Among them, 70 patients underwent liver biopsy after an overnight fast, and 90 patients were biopsied 5 h after an oral glucose tolerance test. Expression differences in genes encoding several fatty acid metabolism-related factors were examined and correlated with hepatic histological changes based on NAFLD activity scores. Prospective patient follow-up continued until June 2018.

Results: The level of fatty acid transport protein 5 (FATP5), which is associated with free fatty acid intake, was significantly and inversely correlated with features of histological progression, including ballooning and fibrosis. This was confirmed by immunohistochemical analysis. Transcript levels of genes encoding fatty acid metabolism-related proteins were comparable between NASH with severe fibrosis and cryptogenic cirrhosis. Furthermore, a prospective cohort study demonstrated that low FATP5 expression was the most significant risk factor for hepatic fat loss.

Conclusions: Decreased hepatic FATP5 expression in NAFLD is linked to histological progression, and may be associated with hepatic fat loss during NASH progression to cirrhosis.

Keywords: Burnout nonalcoholic steatohepatitis; Carnitine palmitoyltransferase 1A; Cirrhosis; Fatty acid transport protein 5; Nonalcoholic fatty liver disease.

MeSH terms

  • Acetyl-CoA Carboxylase / genetics
  • Adipose Tissue / pathology*
  • Adult
  • Aged
  • Biopsy
  • CD36 Antigens / genetics
  • Carnitine O-Palmitoyltransferase / genetics
  • Carnitine O-Palmitoyltransferase / metabolism
  • Coenzyme A Ligases / genetics
  • Disease Progression
  • Fatty Acid Synthase, Type I / genetics
  • Fatty Acid Transport Proteins / genetics*
  • Fatty Acid-Binding Proteins / genetics
  • Fatty Acids, Nonesterified / blood*
  • Female
  • Gene Expression
  • Humans
  • Liver Cirrhosis / etiology
  • Liver Cirrhosis / pathology
  • Long-Chain-Fatty-Acid-CoA Ligase
  • Male
  • Middle Aged
  • Non-alcoholic Fatty Liver Disease / complications
  • Non-alcoholic Fatty Liver Disease / genetics*
  • Non-alcoholic Fatty Liver Disease / metabolism
  • Non-alcoholic Fatty Liver Disease / pathology*
  • PPAR alpha / genetics
  • Prospective Studies
  • RNA, Messenger / metabolism
  • Time Factors

Substances

  • CD36 Antigens
  • FABP1 protein, human
  • Fatty Acid Transport Proteins
  • Fatty Acid-Binding Proteins
  • Fatty Acids, Nonesterified
  • PPAR alpha
  • RNA, Messenger
  • SLC27A5 protein, human
  • CPT1A protein, human
  • Carnitine O-Palmitoyltransferase
  • FASN protein, human
  • Fatty Acid Synthase, Type I
  • Coenzyme A Ligases
  • Long-Chain-Fatty-Acid-CoA Ligase
  • ACACA protein, human
  • Acetyl-CoA Carboxylase